Prednisone administration in recent onset type I diabetes

Antonio Secchi, Matteo R. Pastore, Alessandro Sergi, Antonio E. Pontiroli, Guido Pozza

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The aim of our study was to investigate the efficacy of prednisone to preserve pancreatic β-cell function in patients with recent-onset Type I diabetes mellitus (IDDM). Twenty-five patients with IDDM, aged 24±6 years, entered the trial within 8 weeks of the onset of diabetes. They were allocated, according to a single blind randomized protocol, to one of the following treatments: (A) prednisone (15 mg/day), (B) indomethacin (100 mg/day), (C) placebo. All treatments lasted 8 months and all patients achieved satisfactory metabolic control with a multi-injection regimen (three injections/day) within a few weeks, and maintained it throughout the entire period of observation. Only minor side effects were observed in the prednisone-treated patients. A lower insulin requirement was observed in the prednisone group than in other patients at 12 months (0·33±0·11 vs 0·57±0·06 U/kg/day, P

Original languageEnglish
Pages (from-to)593-600
Number of pages8
JournalJournal of Autoimmunity
Volume3
Issue number5
DOIs
Publication statusPublished - 1990

Fingerprint

Prednisone
Type 1 Diabetes Mellitus
Injections
Indomethacin
Placebos
Observation
Insulin
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Prednisone administration in recent onset type I diabetes. / Secchi, Antonio; Pastore, Matteo R.; Sergi, Alessandro; Pontiroli, Antonio E.; Pozza, Guido.

In: Journal of Autoimmunity, Vol. 3, No. 5, 1990, p. 593-600.

Research output: Contribution to journalArticle

Secchi, Antonio ; Pastore, Matteo R. ; Sergi, Alessandro ; Pontiroli, Antonio E. ; Pozza, Guido. / Prednisone administration in recent onset type I diabetes. In: Journal of Autoimmunity. 1990 ; Vol. 3, No. 5. pp. 593-600.
@article{6839b19597b24322a1b833b2cfc4a82f,
title = "Prednisone administration in recent onset type I diabetes",
abstract = "The aim of our study was to investigate the efficacy of prednisone to preserve pancreatic β-cell function in patients with recent-onset Type I diabetes mellitus (IDDM). Twenty-five patients with IDDM, aged 24±6 years, entered the trial within 8 weeks of the onset of diabetes. They were allocated, according to a single blind randomized protocol, to one of the following treatments: (A) prednisone (15 mg/day), (B) indomethacin (100 mg/day), (C) placebo. All treatments lasted 8 months and all patients achieved satisfactory metabolic control with a multi-injection regimen (three injections/day) within a few weeks, and maintained it throughout the entire period of observation. Only minor side effects were observed in the prednisone-treated patients. A lower insulin requirement was observed in the prednisone group than in other patients at 12 months (0·33±0·11 vs 0·57±0·06 U/kg/day, P",
author = "Antonio Secchi and Pastore, {Matteo R.} and Alessandro Sergi and Pontiroli, {Antonio E.} and Guido Pozza",
year = "1990",
doi = "10.1016/S0896-8411(05)80026-5",
language = "English",
volume = "3",
pages = "593--600",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Prednisone administration in recent onset type I diabetes

AU - Secchi, Antonio

AU - Pastore, Matteo R.

AU - Sergi, Alessandro

AU - Pontiroli, Antonio E.

AU - Pozza, Guido

PY - 1990

Y1 - 1990

N2 - The aim of our study was to investigate the efficacy of prednisone to preserve pancreatic β-cell function in patients with recent-onset Type I diabetes mellitus (IDDM). Twenty-five patients with IDDM, aged 24±6 years, entered the trial within 8 weeks of the onset of diabetes. They were allocated, according to a single blind randomized protocol, to one of the following treatments: (A) prednisone (15 mg/day), (B) indomethacin (100 mg/day), (C) placebo. All treatments lasted 8 months and all patients achieved satisfactory metabolic control with a multi-injection regimen (three injections/day) within a few weeks, and maintained it throughout the entire period of observation. Only minor side effects were observed in the prednisone-treated patients. A lower insulin requirement was observed in the prednisone group than in other patients at 12 months (0·33±0·11 vs 0·57±0·06 U/kg/day, P

AB - The aim of our study was to investigate the efficacy of prednisone to preserve pancreatic β-cell function in patients with recent-onset Type I diabetes mellitus (IDDM). Twenty-five patients with IDDM, aged 24±6 years, entered the trial within 8 weeks of the onset of diabetes. They were allocated, according to a single blind randomized protocol, to one of the following treatments: (A) prednisone (15 mg/day), (B) indomethacin (100 mg/day), (C) placebo. All treatments lasted 8 months and all patients achieved satisfactory metabolic control with a multi-injection regimen (three injections/day) within a few weeks, and maintained it throughout the entire period of observation. Only minor side effects were observed in the prednisone-treated patients. A lower insulin requirement was observed in the prednisone group than in other patients at 12 months (0·33±0·11 vs 0·57±0·06 U/kg/day, P

UR - http://www.scopus.com/inward/record.url?scp=0025168904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025168904&partnerID=8YFLogxK

U2 - 10.1016/S0896-8411(05)80026-5

DO - 10.1016/S0896-8411(05)80026-5

M3 - Article

C2 - 2252527

AN - SCOPUS:0025168904

VL - 3

SP - 593

EP - 600

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

IS - 5

ER -